Mga Batayang Estadistika
| LEI | 549300K1I5L8COCQ8W36 |
| CIK | 1314052 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Anavex Life Sciences Corp.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE |
|
| July 28, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2025 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of i |
|
| July 28, 2025 |
EXHIBIT 1.1 Anavex Life Sciences Corp. COMMON STOCK SALES AGREEMENT July 25, 2025 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Anavex Life Sciences Corp., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from ti |
|
| July 25, 2025 |
Anavex Life Sciences Corp. Up to $150,000,000 of Common Stock As Filed Pursuant to Rule 424(b)(5) Registration No. 333-288661 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 23, 2025) Anavex Life Sciences Corp. Up to $150,000,000 of Common Stock On July 25, 2025, we entered into a Sales Agreement (the “Sales Agreement”) with TD Securities (USA) LLC (“TD Cowen”), relating to the sale of shares of our common stock, par value $0.001 per share, from time to time |
|
| July 21, 2025 |
ANAVEX LIFE SCIENCES CORP. 630 5th Avenue, 20th Floor New York, NY USA 10111 ANAVEX LIFE SCIENCES CORP. 630 5th Avenue, 20th Floor New York, NY USA 10111 July 21, 2025 VIA EDGAR United States Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Attn: Jessica Dickerson Re: Anavex Life Sciences Corp. Request for Acceleration of Registration Statement on Form S-3 File No. 333-288661 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of |
|
| July 21, 2025 |
ANAVEX LIFE SCIENCES CORP. 630 5th Avenue, 20th Floor New York, NY USA 10111 ANAVEX LIFE SCIENCES CORP. 630 5th Avenue, 20th Floor New York, NY USA 10111 July 21, 2025 VIA EDGAR United States Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Attn: Jessica Dickerson Re: Anavex Life Sciences Corp. Request for Acceleration of Registration Statement on Form S-3 File No. 333-288661 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of |
|
| July 14, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Anavex Life Sciences Corp. |
|
| July 14, 2025 |
As filed with the Securities and Exchange Commission on July 14, 2025 As filed with the Securities and Exchange Commission on July 14, 2025 Registration No. |
|
| July 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2025 ANAVEX LIFE SCIENCES CORP. |
|
| July 3, 2025 |
EXHIBIT 10.2 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This Third Amendment to Employment Agreement (the “Amendment”) is executed on this July 3, 2025 (the “Effective Date”), by and between Sandra Boenisch (hereinafter referred to as “Employee”) and Anavex Life Sciences Corp. (together with its subsidiaries, the “Company”). Employee and Company are collectively referred to as the “Parties” and singu |
|
| July 3, 2025 |
EXHIBIT 10.1 FOURTH AMENDMENT TO EMPLOYMENT AGREEMENT This Fourth Amendment to Employment Agreement (this “Amendment”) is executed on this 3rd day of July 2025, and made effective as defined below (the “Effective Date”), by and between Christopher Missling, PhD (hereinafter referred to as “Executive”) and Anavex Life Sciences Corp. (“Employer” and, together with its subsidiaries, the “Company”) an |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of i |
|
| June 13, 2025 |
EXHIBIT 10.1 AMENDMENT NO. 1 TO ANAVEX LIFE SCIENCES CORP. 2022 OMNIBUS INCENTIVE PLAN The Anavex Life Sciences Corp. 2022 Omnibus Incentive Plan (the “Plan”) is hereby amended as follows (capitalized terms used herein and not defined herein shall have the respective meaning ascribed to such terms in the Plan): 1. Section 3 of the Plan shall be amended by adding the following new Section 3.7 immed |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX L |
|
| December 23, 2024 |
EXHIBIT 19.1 ANAVEX LIFE SCIENCES CORP. Insider Trading Policy Anavex Life Sciences Corp. (“Anavex”) has adopted this Insider Trading Policy (the “Policy”) to promote compliance with federal securities laws by directors, officers, employees and consultants of Anavex and its affiliates, as well as any immediate family members sharing the household of any of the foregoing (collectively, the “Covered |
|
| December 23, 2024 |
Subsidiaries of the Registrant EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Incorporation or Organization Anavex Australia Pty Limited Australia Anavex Germany GmbH Germany Anavex Canada Ltd. Ontario, Canada |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37606 ANAVEX LIFE SCIE |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2024 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of i |
|
| July 29, 2024 |
As filed with the Securities and Exchange Commission on July 29, 2024 As filed with the Securities and Exchange Commission on July 29, 2024 Registration No. |
|
| July 29, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Anavex Life Sciences Corp. |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of i |
|
| May 9, 2024 |
EXHIBIT 99.1 Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK – May 9, 2024 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodev |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of inc |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of |
|
| February 13, 2024 |
AVXL / Anavex Life Sciences Corp. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Anavex Life Sciences Corp Title of Class of Securities: Common Stock CUSIP Number: 032797300 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| February 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX L |
|
| November 27, 2023 |
Anavex Life Sciences Corp. Compensation Clawback Policy* EXHIBIT 97.1 ANAVEX LIFE SCIENCES CORP. NASDAQ RULE 5608 EXECUTIVE OFFICER COMPENSATION CLAWBACK Policy Effective NOVEMBER 8, 2023 1. Policy Purpose. The purpose of this Anavex Life Sciences Corp. Nasdaq Rule 5608 Executive Officer Compensation Clawback Policy (this “Policy”) is to enable Anavex Life Sciences Corp. and its subsidiaries and affiliates (the “Company”) to recover Erroneously Awarded |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37606 ANAVEX LIFE SCIE |
|
| November 27, 2023 |
Code of Ethics Adopted on August 1, 2023 EXHIBIT 14.1 BUSINESS CODE OF CONDUCT & ETHICS I. INTRODUCTION/PURPOSE As a business engaged in the discovery, development and commercialization of medicines for the treatment of various diseases, AnavexTM Life Sciences Corp. (the “Anavex” or the “Company”) must always act in a way that reflects the highest standards of corporate behavior and conduct itself in a legal and ethical manner. Each of u |
|
| November 27, 2023 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Incorporation or Organization Anavex Australia Pty Limited Australia Anavex Germany GmbH Germany Anavex Canada Ltd. Ontario, Canada |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of in |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2023 ANAVEX LIFE SCIENCES CORP. |
|
| April 14, 2023 |
EXHIBIT 3.1 AMENDED AND RESTATED BYLAWS OF ANAVEX LIFE SCIENCES CORP. A Nevada Corporation ARTICLE I STOCKHOLDERS SECTION 1 Annual Meeting. Annual meetings of the stockholders of Anavex Life Sciences Corp. (the “Corporation”), shall be held on the day and at the time as may be set by the Board of Directors of the Corporation (the “Board of Directors”) from time to time, at which annual meeting the |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 ANAVEX LIFE SCIENCES CORP. |
|
| February 9, 2023 |
AVXL / Anavex Life Sciences Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Anavex Life Sciences Corp. Title of Class of Securities: Common Stock CUSIP Number: 032797300 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| February 7, 2023 |
EXHIBIT 4.1 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 3, 2023 by and between ANAVEX LIFE SCIENCES CORP., a Nevada corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall hav |
|
| February 7, 2023 |
EX-FILING FEES 2 e4391ex107.htm EXHIBIT 107 Exhibit 107 Calculation of Filing Fee Table Form 424(b)(5) (Form Type) ANAVEX LIFE SCIENCES CORP. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering price |
|
| February 7, 2023 |
EXHIBIT 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the “Agreement”), dated as of February 3, 2023 by and between ANAVEX LIFE SCIENCES CORP., a Nevada corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). Capitalized terms used herein and not otherwise defined herein are defined in Section 1 hereof. WHEREAS: Subject to the ter |
|
| February 7, 2023 |
PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated September 24, 2021) Registration No. |
|
| February 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2023 ANAVEX LIFE SCIENCES CORP. |
|
| February 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX L |
|
| January 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3760 |
|
| December 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 ANAVEX LIFE SCIENCES CORP. |
|
| December 2, 2022 |
EXHIBIT 99.1 ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS, SHOWING STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN GLOBAL CLINICAL STUDY OF PATIENTS WITH EARLY ALZHEIMER’S DISEASE ● Robust, Statistically Significant and Clinically Meaningful Absolute Improvement in Cognitive Function as Measured by ADAS-Cog and ADCS-ADL ● Key Secondary Endpoint CDR |
|
| November 28, 2022 |
EXHIBIT 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Anavex Life Sciences Corp (the ?Company?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: the Company?s common stock, par value $0.001 per share (the ?Common Stock?) Description of Common Stock The following summ |
|
| November 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37606 ANAVEX LIFE SCIE |
|
| August 10, 2022 |
ANAVEX LIFE SCIENCES CORP. 630 5th Avenue, 20th Floor New York, NY 10111 August 10, 2022 ANAVEX LIFE SCIENCES CORP. 630 5th Avenue, 20th Floor New York, NY 10111 August 10, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, DC 20549 Attention: Jeanne Baker Terence O?Brien Re: Anavex Life Sciences Corp. Form 10-K for Fiscal Year Ended September 30, 2021 Filed November 24, 2021 File No. 001-37606 Dear Ms. Baker |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE |
|
| June 10, 2022 |
EX-FILING FEES 4 e3822ex107.htm EXHIBIT 107 Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Anavex Life Sciences Corp. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of R |
|
| June 10, 2022 |
As filed with the Securities and Exchange Commission on June 10, 2022 As filed with the Securities and Exchange Commission on June 10, 2022 Registration No. |
|
| May 27, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of in |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE |
|
| April 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of |
|
| April 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of |
|
| April 8, 2022 |
EXHIBIT 10.1 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This Third Amendment to Employment Agreement (this ?Amendment?) is executed on this seventh day of April 2022, and made effective as defined below (the ?Effective Date?), by and between Christopher Missling, PhD (hereinafter referred to as ?Executive?) and Anavex Life Sciences Corp. (?Employer? and, together with its subsidiaries, the ?Company?) |
|
| April 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2022 ANAVEX LIFE SCIENCES CORP. |
|
| March 4, 2022 |
Letter from BDO USA LLP to the Securities and Exchange Commission dated March 4, 2022 EXHIBIT 16.1 March 4, 2022 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on March 1, 2022, to be filed by our former client, Anavex Life Sciences Corp.. We agree with the statements made in response to that Item insofar as they relate to our Firm. Very truly yours, |
|
| March 4, 2022 |
Anavex Life Sciences Announces Change of Auditor to Grant Thornton LLP EXHIBIT 99.1 Anavex Life Sciences Announces Change of Auditor to Grant Thornton LLP NEW YORK ? March 4, 2022 ? Anavex Life Sciences Corp. (?Anavex? or the ?Company?) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer?s disease, Parkinson?s disease, Rett syndrom |
|
| March 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2022 ANAVEX LIFE SCIENCES CORP. |
|
| March 4, 2022 |
Exhibit 10.1 AMENDMENT NO. 2 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDMENT NO. 2 (the ?Amendment?) to the Amended and Restated Employment Agreement, dated October 4, 2017 (the ?Employment Agreement?) is dated February 28, 2022 with an effective date of March 1, 2022, is by and between Anavex Life Sciences Corp. (the ?Company? or ?Anavex?), and Sandra Boenisch (the ?Employee?). Except |
|
| February 9, 2022 |
AVXL / Anavex Life Sciences Corp / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv0263-anavexlifesciencescor.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Anavex Life Sciences Corp. Title of Class of Securities: Common Stock CUSIP Number: 032797300 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule p |
|
| February 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX L |
|
| February 4, 2022 |
EXHIBIT 99.1 Anavex Life Sciences Provides Supplemental Information on ANAVEX?2-73 (Blarcamesine) AVATAR Phase 3 Trial for the Treatment of Adult Patients with Rett Syndrome NEW YORK ? February 4, 2022 ? Anavex Life Sciences Corp. (?Anavex? or the ?Company?) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and |
|
| February 4, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2022 ANAVEX LIFE SCIENCES CORP. |
|
| February 2, 2022 |
EXHIBIT 99.1 |
|
| February 2, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2022 ANAVEX LIFE SCIENCES CORP. |
|
| November 24, 2021 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Incorporation or Organization Anavex Australia Pty Limited Australia Anavex Germany GmbH Germany Anavex Canada Ltd. Ontario, Canada |
|
| November 24, 2021 |
Exhibit 3.1 |
|
| November 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37606 ANAVEX LIFE SCIE |
|
| September 27, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2021 ANAVEX LIFE SCIENCES CORP. |
|
| September 27, 2021 |
Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market® Exhibit 99.1 Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market? NEW YORK ? September 27, 2021 ? Anavex Life Sciences Corp. (?Anavex? or the ?Company?) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer?s disease, Parkinson?s disease, R |
|
| September 24, 2021 |
As filed with the Securities and Exchange Commission on September 24, 2021 As filed with the Securities and Exchange Commission on September 24, 2021 Registration No. |
|
| September 13, 2021 |
EXHIBIT 99.1 |
|
| September 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2021 ANAVEX LIFE SCIENCES CORP. |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE |
|
| June 24, 2021 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of June 22, 2021, between Anavex Life Sciences Corp., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions |
|
| June 24, 2021 |
Exhibit 10.1 Execution Version June 21, 2021 STRICTLY CONFIDENTIAL Anavex Life Sciences Corp. 51 West 52nd Street, 7th Floor New York, NY 10019 Attn: Christopher Missling, Ph.D., Chief Executive Officer Dear Dr. Missling: This letter agreement (this ?Agreement?) constitutes the agreement between Anavex Life Sciences Corp. (the ?Company?) and H.C. Wainwright & Co., LLC (?Wainwright?), that Wainwrig |
|
| June 24, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2021 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of i |
|
| June 24, 2021 |
Anavex Life Sciences Corp. 2,380,953 Shares of Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated July 15, 2019) Registration No. |
|
| June 24, 2021 |
Anavex Life Sciences Announces $50 Million Registered Direct Offering Exhibit 99.1 Anavex Life Sciences Announces $50 Million Registered Direct Offering NEW YORK ? June 22, 2021 ? Anavex Life Sciences Corp. (?Anavex? or the ?Company?) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer?s disease, Parkinson?s disease, Rett syndrome |
|
| May 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2021 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of in |
|
| May 28, 2021 |
Exhibit 3.1 |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE |
|
| April 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of |
|
| April 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 98-0608404 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification Number) 51 West 52nd Street, 7th Floor New York, NY 10019-6163 Telephon |
|
| April 1, 2021 |
- PRELIMINARY INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX L |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* ANAVEX LIFE SCIENCES CORP. (Name of Issuer) Common Stock, PAR VALUE $0.001 per share (Title of Class of Securities) 032797300 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 16, 2021 |
Anavex Life Sciences Corp. Up to $50,000,000 Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated July 15, 2019) Registration No. |
|
| December 28, 2020 |
Exhibit 99.1 Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program Updates Conference Call and Webcast Today at 4:30 p.m. ET NEW YORK – December 28, 2020 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopm |
|
| December 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37606 ANAVEX LIFE SCIE |
|
| December 28, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2020 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer |
|
| December 28, 2020 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Incorporation or Organization Anavex Australia Pty Limited Australia Anavex Germany GmbH Germany Anavex Canada Ltd. Ontario, Canada |
|
| December 15, 2020 |
Exhibit 99.1 Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome Primary safety, pharmacokinetics and secondary efficacy endpoints met, with consistent improvements in RSBQ Total scores and CGI-I Efficacy endpoints demonstrated statistically significa |
|
| December 15, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2020 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer |
|
| November 6, 2020 |
The Presentation dated November 6, 2020 Exhibit 99.2 |
|
| November 6, 2020 |
Exhibit 99.1 Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Presented at CTAD 2020 Conference Statistically significant improvements in CDR system Cognitive Domain of Attention assessed by Choice Reaction Time (p = 0.039) and Digital Vigilance (p = 0.008) Statistically significant dose-dependent improvements in Episodic |
|
| November 6, 2020 |
Other Events, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2020 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer o |
|
| October 15, 2020 |
Exhibit 99.1 Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Clinically meaningful, dose-dependent, and statistically significant improvements in the Cognitive Drug Research (CDR) computerized assessment system analysis Company to host conference call today at 8:30 AM ET NE |
|
| October 15, 2020 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2020 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer o |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE |
|
| July 2, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2020 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of in |
|
| July 2, 2020 |
Anavex Life Sciences Corp. Up to $25,272,213 Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated July 15, 2019) Registration No. |
|
| July 2, 2020 |
Exhibit 10.1 FIRST AMENDMENT TO PURCHASE AGREEMENT THIS FIRST AMENDMENT TO PURCHASE AGREEMENT (this “First Amendment”), dated as of July 1, 2020, by and between ANAVEX LIFE SCIENCES CORP., a Nevada corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). WHEREAS, the Company and the Investor entered into that certain Purchase Agreemen |
|
| May 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE |
|
| May 1, 2020 |
Anavex Life Sciences Corp. Up to $30,331,854 Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated July 15, 2019) Registration No. |
|
| May 1, 2020 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2020 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of inc |
|
| May 1, 2020 |
Anavex Life Sciences Corp. Up to $50,000,000 Common Stock 424B5 1 e1888424b5.htm 424B5 PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated July 15, 2019) Registration No. 333-232550 Anavex Life Sciences Corp. Up to $50,000,000 Common Stock On May 1 2020, we entered into an amended and restated sales agreement, or the Sales Agreement, with Cantor Fitzgerald & Co., or Cantor Fitzgerald, and SVB Leerink LLC, or SVB Leerink, and toget |
|
| May 1, 2020 |
Exhibit 1.1 ANAVEX LIFE SCIENCES CORP. Shares of Common Stock (par value $0.001 per share) Amended and Restated Sales Agreement May 1, 2020 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 SVB Leerink LLC 1301 Avenue of the Americas, 12th Floor New York, NY 10019 Ladies and Gentlemen: Reference is made to the Controlled Equity OfferingSM Sales Agreement, dated as of July 6, 2018 (the “Or |
|
| April 8, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2020 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of i |
|
| March 23, 2020 |
AVXL / Anavex Life Sciences Corp. DEFA14A - - DEFA14A DEFA14A 1 e1821defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, For Use of the Commission Only |
|
| February 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, Fo |
|
| February 14, 2020 |
AVXL / Anavex Life Sciences Corp. / Park West Asset Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* ANAVEX LIFE SCIENCES CORP. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 032797300 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 6, 2020 |
Exhibit 10.1 AMENDMENT NO. 1 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDMENT NO. 1 (the “Amendment”) to the Amended and Restated Employment Agreement, dated October 4, 2017 (the “Employment Agreement”) is dated February 4, 2020 with an effective date of March 1, 2020, is by and between Anavex Life Sciences Corp. (the “Company” or “Anavex”), and Sandra Boenisch (the “Employee”). Except |
|
| February 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAV |
|
| December 16, 2019 |
AVXL / Anavex Life Sciences Corp. 10-K - Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37606 ANAVEX LIFE SCIE |
|
| December 16, 2019 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Incorporation or Organization Anavex Australia Pty Limited Australia Anavex Germany GmbH Germany Anavex Canada Ltd. Ontario, Canada |
|
| September 17, 2019 |
AVXL / Anavex Life Sciences Corp. POS AM - - FORM POS AM As filed with the Securities and Exchange Commission on September 17, 2019 Registration No. |
|
| September 16, 2019 |
AVXL / Anavex Life Sciences Corp. AW - - AW AW 1 aw091619anavexlife.htm AW ANAVEX LIFE SCIENCES CORP. 51 W. 52nd Street, 7th Floor New York, NY 10019-6163 September 16, 2019 VIA EDGAR United States Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Anavex Life Sciences Corp. Form AW - Request for Withdrawal Amendment No. 4 to Registration Statement on Form S-3 File No. 333-207600 Ladies and Gentlemen: Pursuant t |
|
| September 13, 2019 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2019 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer |
|
| September 13, 2019 |
Anavex Life Sciences Corp. Up to $15,514,532 of Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated July 15, 2019) Registration No. |
|
| September 13, 2019 |
AVXL / Anavex Life Sciences Corp. S-3/A - - AMENDMENT NO. 4 TO FORM S-3 As filed with the Securities and Exchange Commission on September 13, 2019 Registration No. |
|
| August 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE |
|
| July 12, 2019 |
AVXL / Anavex Life Sciences Corp. CORRESP - - ANAVEX LIFE SCIENCES CORP. 51 W. 52nd Street, 7th Floor New York, NY 10019-6163 July 12, 2019 VIA EDGAR United States Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Attn: Michael Killoy Re: Anavex Life Sciences Corp. Request for Acceleration of Registration Statement on Form S-3 File No. 333-232550 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of |
|
| July 3, 2019 |
AVXL / Anavex Life Sciences Corp. S-3 - - REGISTRATION STATEMENT S-3 1 fs32019anavexlifesciences.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on July 3, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 98-0608404 (State or oth |
|
| June 12, 2019 |
Anavex Life Sciences Corp. Up to $21,159,993 Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated September 6, 2016) Registration No. |
|
| June 12, 2019 |
Exhibit 10.1 EXECUTION VERSION PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the “Agreement”), dated as of June 7, 2019, by and between ANAVEX LIFE SCIENCES CORP., a Nevada corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). Capitalized terms used herein and not otherwise defined herein are defined in Section 1 hereof. WHEREAS: Sub |
|
| June 12, 2019 |
Financial Statements and Exhibits, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2019 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission File Number) (IRS E |
|
| June 12, 2019 |
Exhibit 4.1 Execution Version Registration Rights Agreement REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 7, 2019 by and between ANAVEX LIFE SCIENCES CORP., a Nevada corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with it permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined her |
|
| May 9, 2019 |
Exhibit 10.1 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to Employment Agreement (the “Amendment”) is executed on this 3rd day of May 2019 (the “Effective Date”), by and between Christopher Missling, PhD (hereinafter referred to as “Executive”) and Anavex Life Sciences Corp. (“Employer” and, together with its subsidiaries, the “Company”) and serves to amend that certain Employme |
|
| May 9, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE |
|
| May 9, 2019 |
Exhibit 3.1 |
|
| April 8, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2019 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of i |
|
| March 18, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2019 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of |
|
| March 16, 2019 |
Anavex Life Sciences Corp. Up to $9,711,390 Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated September 6, 2016) Registration No. |
|
| February 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ANAVEX LIFE SCIENCES CORP. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 032797300 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 11, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of |
|
| February 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX L |
|
| January 31, 2019 |
AVXL / Anavex Life Sciences Corp. PRE 14A PRE 14A 1 s115426pre14a.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy |
|
| January 25, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3760 |
|
| December 12, 2018 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Incorporation or Organization Anavex Australia Pty Limited Australia Anavex Germany GmbH Germany Anavex Canada Ltd. Ontario, Canada |
|
| December 12, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37606 ANAVEX LIFE SCIE |
|
| August 9, 2018 |
AVXL / Anavex Life Sciences Corp. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37606 ANAVEX LIFE |
|
| July 6, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2018 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of in |
|
| July 6, 2018 |
Exhibit 1.1 ANAVEX LIFE SCIENCES CORP. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement July 6, 2018 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Anavex Life Sciences Corp., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows: 1. Iss |
|
| July 6, 2018 |
Anavex Life Sciences Corp. Up to $50,000,000 Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated September 6, 2016) Registration No. |
|
| May 10, 2018 |
AVXL / Anavex Life Sciences Corp. 10-Q (Quarterly Report) 10-Q 1 s11004510q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Nu |
|
| April 20, 2018 |
Submission of Matters to a Vote of Security Holders 8-K 1 s1097348k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2018 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Comm |
|
| March 8, 2018 |
Exhibit 99.1 Anavex Life Sciences Strengthens Management Team and Board of Directors Company Appoints Stephan Toutain as Senior Vice President of Operations and Claus van der Velden to Board of Directors New York — March 5, 2018 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatmen |
|
| March 8, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2018 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 001-37606 98-0608404 (State or other jurisdiction (Commission (IRS Employer of i |
|
| March 8, 2018 |
AVXL / Anavex Life Sciences Corp. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, For Use of |
|
| February 14, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ANAVEX LIFE SCIENCES CORP. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 032797300 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 7, 2018 |
AVXL / Anavex Life Sciences Corp. 10-Q (Quarterly Report) 10-Q 1 s10893510q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File |
|
| December 11, 2017 |
Exhibit 99.1 ANAVEX LIFE SCIENCES CORP. Insider Trading Policy Anavex Life Sciences Corp. (?Anavex?) has adopted this Insider Trading Policy (the ?Policy?) to promote compliance with federal securities laws by directors, officers, employees and consultants of Anavex and its affiliates, as well as any immediate family members sharing the household of any of the foregoing (collectively, the ?Covered |
|
| December 11, 2017 |
Exhibit 10.7 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT, dated October 4, 2017 with an effective date of October 1, 2017 (the ?Agreement?), is by and between Anavex Life Sciences Corp. (the ?Company? or ?Anavex?), and Sandra Boenisch (the ?Employee?). The Company and the Employee are referred to each individually as a ?Party? and collectively as the ?P |
|
| December 11, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☐ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37606 ANAVEX LIFE SCIE |
|
| December 11, 2017 |
SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Jurisdiction of Incorporation or Organization Anavex Australia Pty Limited Australia Anavex Germany GmbH Germany Anavex Canada Ltd. Ontario, Canada |
|
| October 6, 2017 |
8-K 1 s1077088k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2017 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 000-51652 98-0608404 (State or other jurisdiction (Com |
|
| September 7, 2017 |
Anavex Life Sciences Corp. 5,000,000 Shares of Common Stock Offered by a Selling Security Holder 424B3 1 s107410424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-218292 Anavex Life Sciences Corp. 5,000,000 Shares of Common Stock Offered by a Selling Security Holder This prospectus relates to the sale by Lincoln Park Capital Fund, LLC, or Lincoln Park, of up to 5,000,000 shares of the common Stock, par value $0.001 per share of Anavex Life Sciences Corp., a Nevada corporati |
|
| August 11, 2017 |
As filed with the Securities and Exchange Commission on August 11, 2017 Registration No. |
|
| August 7, 2017 |
10-Q 1 s10702910q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Num |
|
| June 9, 2017 |
CORRESP 1 filename1.htm ANAVEX LIFE SCIENCES CORP. 51 W. 52nd Street, 7th Floor New York, NY 10019-6163 June 9, 2017 VIA EDGAR United States Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Attn: Hillary Daniels Re: Anavex Life Sciences Corp. Request for Acceleration of Registration Statement on Form S-3 File No. 333-218292 Ladies and Gentlemen: Pursuant to Rule 461 unde |
|
| May 26, 2017 |
As filed with the Securities and Exchange Commission on May 26, 2017 Registration No. |
|
| May 10, 2017 |
Exhibit 99.1 ANAVEX LIFE SCIENCES CORP. Investment Policy & Guidelines Purpose: The purpose of this policy is to set forth the guidelines for managing the available cash of Anavex Life Sciences Corp. by its designated money managers. The funds are to be invested to assure preservation of capital, liquidity, and security of corporate funds while providing a reasonable return of investment. Objectiv |
|
| May 10, 2017 |
Quarterly Report - QUARTERLY REPORT 10-Q 1 s10608510q.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2017 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commis |
|
| April 21, 2017 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2017 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 000-51652 98-0608404 (State or other jurisdiction (Commission (IRS Employer of |
|
| March 17, 2017 |
Certificate of Amendment (PURSUANT TO NRS 78.385 AND 78.390) Exhibit 99.1 BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov Certificate of Amendment (PURSUANT TO NRS 78.385 AND 78.390) USE BLACK INK ONLY ? DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Amendment to Articles of Incorporation For Nevada Profit Corporations (Pursuant to NRS 78.385 and 78.390 - |
|
| March 17, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of |
|
| March 10, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of |
|
| February 27, 2017 |
Exhibit A |
|
| February 27, 2017 |
PRE 14A 1 s105424pre14a.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: þ Preliminary Proxy |
|
| February 13, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2017 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 000-51652 98-0608404 (State or other jurisdiction (Commission (IRS Employer o |
|
| February 13, 2017 |
Anavex Life Sciences Strengthens Board of Directors Exhibit 99.1 Anavex Life Sciences Strengthens Board of Directors NEW YORK ? February 13, 2017 ? Anavex Life Sciences Corp. (?Anavex? or the ?Company?) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer?s disease, other central nervous system (CNS) diseases, pain |
|
| February 13, 2017 |
AVXL / Anavex Life Sciences Corp. / Park West Asset Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ANAVEX LIFE SCIENCES CORP. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 032797300 (CUSIP Number) February 1, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 7, 2017 |
10-Q 1 s10522210q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2016 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File |
|
| December 14, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2016 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-51652 ANAVEX LIFE SCIE |
|
| December 14, 2016 |
Exhibit 14.1 BUSINESS CODE OF CONDUCT & ETHICS I. Purpose As a business engaged in the discovery, development and commercialization of medicines for the treatment of various diseases, AnavexTM Life Sciences Corp. (the ?Anavex? or the ?Company?) must always act in a way that reflects the highest standards of corporate behavior. Each of us must always exercise good judgment and common sense in makin |
|
| October 21, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2016 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 000-51652 98-0608404 (State or other jurisdiction (Commission (IRS Employer o |
|
| October 21, 2016 |
Christopher U. Missling, MS, PhD, MBA, President and CEO of Anavex Life Sciences Corp. Exhibit 99.1 Christopher U. Missling, MS, PhD, MBA, President and CEO of Anavex Life Sciences Corp. Dr. Missling, President and CEO of Anavex, has over 20 years of healthcare industry experience within large pharmaceutical companies, the biotech industry and investment banking. Prior to joining Anavex, he served as the Chief Financial Officer of Curis and ImmunoGen. In addition, at Aventis (now Sa |
|
| September 12, 2016 |
424B3 1 s104089424b3.htm 424B3 PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-207600 Anavex Life Sciences Corp. $100,000,000 of Shares of Common Stock and Warrants 6,754,609 Shares of Common Stock Offered by Selling Security Holder Anavex Life Sciences Corp., a Nevada corporation (“us”, “we”, “our”, “Anavex” or the “Company”) may offer and sell from time to time, in one or more s |
|
| September 1, 2016 |
ANAVEX LIFE SCIENCES CORP. 51 W. 52nd Street, 7th Floor New York, NY 10019-6163 September 1, 2016 VIA EDGAR Mr. John Reynolds Assistant Director United States Securities and Exchange Commission 100 F. Street, N.E. Mail Stop 3561 Washington, DC 20549 Re: Anavex Life Sciences Corp. Request for Acceleration of Registration Statement on Form S-3 Initially Filed October 26, 2015 File No. 333-207600 Dea |
|
| August 31, 2016 |
As filed with the Securities and Exchange Commission on August 31, 2016 Registration No. |
|
| August 30, 2016 |
CORRESP 1 filename1.htm Anavex Life Sciences Corp. 51 West 52nd Street, 7th Floor New York, NY 10019-6163 August 30, 2016 John Reynolds Assistant Director United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Tel: (202) 551-3715 Re: Anavex Life Sciences Corp. Amendment No. 2 to Registration Statement on Form S-3 Filed August 26, 20 |
|
| August 26, 2016 |
As filed with the Securities and Exchange Commission on August 26, 2016 Registration No. |
|
| August 26, 2016 |
ANAVEX LIFE SCIENCES CORP. 51 West 52nd Street, 7th Floor New York, New York 10019-6163 August 26, 2016 VIA EDGAR John Reynolds, Assistant Director United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Tel: (202) 551-3715 Re: Anavex Life Sciences Corp. Registration Statement on Form S-3 Filed October 26, 2015, as Amended on August |
|
| August 26, 2016 |
ANAVEX LIFE SCIENCES CORP. 51 West 52nd Street, 7th Floor New York, New York 10019-6163 August 26, 2016 VIA EDGAR John Reynolds, Assistant Director United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Tel: (202) 551-3715 Re: Anavex Life Sciences Corp. Registration Statement on Form S-3 Filed October 26, 2015, as Amended on August |
|
| August 18, 2016 |
As filed with the Securities and Exchange Commission on August 18, 2016 Registration No. |
|
| August 18, 2016 |
Anavex Life Sciences Corp.: Exhibit 10.2 - Filed by newsfilecorp.com Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of October 21, 2015, by and between ANAVEX LIFE SCIENCES CORP., a Nevada corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with it permitted assigns, the ?Buyer?). Ca |
|
| August 18, 2016 |
As filed with the Securities and Exchange Commission on August 18, 2016 Registration No. |
|
| August 18, 2016 |
Anavex Life Sciences Corp.: Exhibit 10.1 - Filed by newsfilecorp.com Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the ?Agreement?), dated as of October 21, 2015, by and between ANAVEX LIFE SCIENCES CORP., a Nevada corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the ?Investor?). WHEREAS: Subject to the terms and conditions set fort |
|
| August 18, 2016 |
Anavex Life Sciences Corp.: Exhibit 10.1 - Filed by newsfilecorp.com Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the ?Agreement?), dated as of October 21, 2015, by and between ANAVEX LIFE SCIENCES CORP., a Nevada corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the ?Investor?). WHEREAS: Subject to the terms and conditions set fort |
|
| August 18, 2016 |
Anavex Life Sciences Corp.: Exhibit 10.2 - Filed by newsfilecorp.com Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of October 21, 2015, by and between ANAVEX LIFE SCIENCES CORP., a Nevada corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with it permitted assigns, the ?Buyer?). Ca |
|
| August 18, 2016 |
ANAVEX LIFE SCIENCES CORP. 51 West 52nd Street, 7th Floor New York, New York 10019-6163 August 18, 2016 VIA EDGAR John Reynolds, Assistant Director United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Tel: (202) 551-3715 Re: Anavex Life Sciences Corp. Registration Statement on Form S-3 Filed October 26, 2015 File No. 333-207600 De |
|
| August 11, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2016 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51652 ANAVEX LIFE |
|
| July 22, 2016 |
Exhibit 10.1 AMENDED AND RESTATED FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This Amended and Restated First Amendment to Employment Agreement (the ?Amendment?) is executed on this 18th day of July 2016, and made effective as defined below (the ?Effective Date?), by and between Christopher Missling, PhD (hereinafter referred to as ?Executive?) and Anavex Life Sciences Corp. (?Employer? and, together |
|
| July 22, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2016 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 000-51652 98-0608404 (State or other jurisdiction (Commission (IRS Employer of i |
|
| July 7, 2016 |
Exhibit 10.1 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to Employment Agreement (the ?Amendment?) is executed on this 5th day of July 2016 (the ?Effective Date?), by and between Christopher Missling, PhD (hereinafter referred to as ?Executive?) and Anavex Life Sciences Corp. (?Employer? and, together with its subsidiaries, the ?Company?) and serves to amend that certain Employmen |
|
| July 7, 2016 |
8-K 1 s1036668k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2016 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 000-51652 20-8365999 (State or other jurisdiction (C |
|
| June 23, 2016 |
Anavex Life Sciences 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2016 Anavex Life Sciences Corp. (Exact name of registrant as specified in its charter) Nevada 000-51652 98-0608404 (State or other jurisdiction (Commission (IRS Employer of i |
|
| June 23, 2016 |
Exhibit 99.1 |
|
| June 23, 2016 |
Anavex to Present at the 2016 Rett Syndrome Symposium Exhibit 99.2 Anavex to Present at the 2016 Rett Syndrome Symposium NEW YORK – June 23, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL) a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain an |
|
| May 11, 2016 |
10-Q 1 s10319910q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2016 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission Fi |
|
| May 10, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2016 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 000-51652 98-0608404 (State or other jurisdiction (Commission (IRS Employer of inc |
|
| May 6, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2016 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 000-51652 98-0608404 (State or other jurisdiction (Commission (IRS Employer of inc |
|
| May 6, 2016 |
Exhibit 99.1 |
|
| April 1, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of |
|
| February 8, 2016 |
10-Q 1 s10259610q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2015 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File |
|
| December 29, 2015 |
Exhibit 10.92 EMPLOYMENT AGREEMENT THIS AGREEMENT, dated September 17, 2015 with an effective date of October 1, 2015 (the ?Agreement?), is by and between Anavex Life Sciences Corp. (the ?Company? or ?Anavex?), and Sandra Boenisch (the ?Employee?). The Company and the Employee are referred to each individually as a ?Party? and collectively as the ?Parties.? RECITALS WHEREAS, the Company desires to |
|
| December 29, 2015 |
Exhibit 10.91 anavex life sciences corp. 2015 OMNIBUS INCENTIVE PLAN Anavex Life Sciences Corp. sets forth herein the terms and conditions of its 2015 Omnibus Incentive Plan, as follows: 1. PURPOSE The Plan is intended to enhance the Company?s and its Affiliates? ability to attract and retain highly qualified officers, Non-Employee Directors, key employees and Consultants, and to motivate such off |
|
| December 29, 2015 |
10-K 1 s10239710k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2015 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file nu |
|
| October 26, 2015 |
Anavex Life Sciences FORM 8-K (Current Report/Significant Event) Anavex Life Sciences Corp.: Form 8-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2015 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 000-51652 20 |
|
| October 26, 2015 |
S-3 1 s102056forms3.htm FORM S-3 As filed with the Securities and Exchange Commission on October 23, 2015 Registration No.- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 20-8365999 (State or other jurisdiction of (IRS Em |
|
| October 26, 2015 |
Anavex Life Sciences Corp.: Exhibit 10.2 - Filed by newsfilecorp.com Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of October 21, 2015, by and between ANAVEX LIFE SCIENCES CORP., a Nevada corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with it permitted assigns, the ?Buyer?). Ca |
|
| October 26, 2015 |
Anavex Life Sciences Corp.: Exhibit 10.1 - Filed by newsfilecorp.com Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the ?Agreement?), dated as of October 21, 2015, by and between ANAVEX LIFE SCIENCES CORP., a Nevada corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the ?Investor?). WHEREAS: Subject to the terms and conditions set fort |
|
| October 23, 2015 |
8-A12B 1 form8a12b.htm FORM 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 20-8365999 (State of incorporation or organization) (I.R.S. Employer Iden |
|
| October 7, 2015 |
8-K/A 1 form8ka.htm FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2015 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 000-51652 20-8365999 (State or other jurisdic |
|
| October 7, 2015 |
Anavex Prepares for Uplisting to NASDAQ, Announces Reverse Stock Split Anavex Life Sciences Corp.: Exhibit 99.1 - Filed by newsfilecorp.com Anavex Prepares for Uplisting to NASDAQ, Announces Reverse Stock Split NEW YORK, NY ? October 6, 2015 ? Anavex Life Sciences Corp. (?Anavex? or the ?Company?) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer?s disease, other central nervous system (CNS) diseases, pain, and va |
|
| October 6, 2015 |
Anavex Life Sciences Corp.: Exhibit 3.1 - Filed by newsfilecorp.com *090303* *090303 BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov Certificate of Change Pursuant to NRS 78.209 USE BLACK INK ONLY - DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Change filed Pursuant to NRS 78.209 For Nevada Pro |
|
| October 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2015 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 000-51652 20-8365999 (State or other jurisdiction (Commission (IRS Employer of |
|
| October 6, 2015 |
Anavex Prepares for Uplisting to NASDAQ, Announces Reverse Stock Split Anavex Life Sciences Corp.: Exhibit 99.1 - Filed by newsfilecorp.com Anavex Prepares for Uplisting to NASDAQ, Announces Reverse Stock Split NEW YORK, NY ? October 6, 2015 ? Anavex Life Sciences Corp. (?Anavex? or the ?Company?) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer?s disease, other central nervous system (CNS) diseases, pain, and va |
|
| September 28, 2015 |
Anavex Life Sciences Corp.: Exhibit 99.1- Filed by newsfilecorp.com ANAVEX LIFE SCIENCES CORP. INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS September 15, 2015 and September 30, 2014 (Unaudited) ASSETS September 15, September 30, 2015 2014 Current Cash $ 13,101,846 $ 7,262,138 Prepaid expenses 79,321 89,117 Total current assets 13,181,167 7,351,255 Equipment 1,501 2,247 Total assets $ 13,182,668 $ |
|
| September 28, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 form8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 28, 2015 Anavex Life Sciences Corp. (Exact name of registrant as specified in its charter) Nevada 000-51652 20-8365999 (State or other jurisdiction |
|
| August 14, 2015 |
10-Q 1 form10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2015 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission Fi |
|
| July 23, 2015 |
Anavex Life Sciences FORM 8-K (Current Report/Significant Event) Anavex Life Sciences Corp.: Form 8-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2015 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 000-51652 20-83 |
|
| July 23, 2015 |
Anavex Life Sciences Corp.: Exhibit 99.1 - Filed by newsfilecorp.com ANAVEX LIFE SCIENCES CORP. INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS July 15, 2015 and September 30, 2014 (Unaudited) ASSETS July 15, September 30, 2015 2014 Current Cash $ 8,025,039 $ 7,262,138 Prepaid expenses 16,054 89,117 Total current assets 8,041,093 7,351,255 Equipment 1,749 2,247 Total assets $ 8,042,842 $ 7,353,502 L |
|
| July 8, 2015 |
9,975,267 Shares of Common Stock Anavex Life Sciences Corp.: Form 424B3 - Filed by newsfilecorp.com Filed pursuant to Rule 424(b)(3) Registration No. 333-191682 PROSPECTUS 9,975,267 Shares of Common Stock This prospectus relates to the offer and sale of up to 9,975,267 shares of the common stock, par value $0.001, of Anavex Life Sciences Corp., a Nevada corporation, by Lincoln Park Capital Fund, LLC, or Lincoln Park, or the selli |
|
| June 19, 2015 |
POS AM 1 posam.htm FORM POS AM As filed with the U.S. Securities and Exchange Commission on June 19, 2015 Registration No. 333-191682 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ANAVEX LIFE SCIENCES CORP. (Name of Registrant As Specified in its Charter) Nevada 8731 98-0608404 |
|
| June 17, 2015 |
Anavex Life Sciences FORM 8-K (Current Report/Significant Event) Anavex Life Sciences Corp.: Form 8-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2015 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 000-51652 20-83 |
|
| May 29, 2015 |
ANAVEX LIFE SCIENCES CORP. CONSOLIDATED BALANCE SHEETS Anavex Life Sciences Corp. - Exhibit 99.1 - Filed by newsfilecorp.com ANAVEX LIFE SCIENCES CORP. CONSOLIDATED BALANCE SHEETS ASSETS May 8, September 30, 2015 2014 Current Cash $ 6,746,263 $ 7,262,138 Prepaid expenses 31,445 89,117 Total current assets 6,777,708 7,351,255 Equipment 1,749 2,247 Total assets $ 6,779,457 $ 7,353,502 LIABILITIES AND STOCKHOLDERS' EQUITY Current Accounts payable and acc |
|
| May 29, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits Anavex Life Sciences Corp.: Form 8-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2015 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 000-51652 98-060 |
|
| May 14, 2015 |
Anavex Life Sciences Corp. - Form 10-Q - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2015 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the |
|
| March 30, 2015 |
Anavex Life Sciences FORM 8-K (Current Report/Significant Event) Anavex Life Sciences Corp.: Form 8-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2015 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 000-51652 98-0 |
|
| March 30, 2015 |
Anavex Life Sciences Corp. - Exhibit 3.1 - Filed by newsfilecorp.com BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov Certificate of Amendment (PURSUANT TO NRS 78.385 AND 78.390) USE BLACK INK ONLY - DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Amendment to Articles of Incorporation For Nevada |
|
| March 25, 2015 |
15,486,358 Shares of Common Stock Anavex Life Sciences Corp.: Form 424B3 - Filed by newsfilecorp.com Filed Pursuant to Rule 424(b)(3) Registration No. 333-202533 PROSPECTUS 15,486,358 Shares of Common Stock This prospectus relates to the sale or other disposition from time to time of shares of common stock, par value $0.001 per share, of Anavex Life Sciences Corp., a Nevada corporation, by certain of our security holders (the ?Sel |
|
| March 5, 2015 |
Registration Statement - FORM S-1 Anavex Life Sciences Corp.: Form S-1 - Filed by newsfilecorp.com As Filed with the Securities and Exchange Registration No. Commission on March 5, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ANAVEX LIFE SCIENCES CORP. (Name of Registrant As Specified in its Charter) Nevada 8731 20-8365999 (State or Ot |
|
| February 17, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2014 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51652 ANAV |
|
| February 13, 2015 |
Anavex Life Sciences Corp. - Certificate of Amendment - Filed by newsfilecorp.com |
|
| February 13, 2015 |
Anavex Life Sciences Corp. - Certificate of Amendment - Filed by newsfilecorp.com Schedule 1 Article 3 of the Articles of Incorporation of Anavex Life Sciences Corp. is hereby amended to add the following paragraph: "In addition to the authorized shares of common stock, the corporation is authorized to issue 10,000,000 shares of preferred stock. The preferred stock may be issued from time to time |
|
| February 13, 2015 |
AVXL / Anavex Life Sciences Corp. DEF 14A - - FORM DEF 14A Anavex Life Sciences Corp. - Schedule DEF14A - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check |
|
| January 30, 2015 |
Anavex Life Sciences Corp. - Certificate of Amendment - Filed by newsfilecorp.com |
